Pulmonx (LUNG) Resumen de Acciones
Pulmonx Corporation, una empresa de tecnología médica en fase comercial que ofrece un tratamiento mínimamente invasivo para pacientes con enfisema grave, una forma de enfermedad pulmonar obstructiva crónica. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 3/6 |
| Crecimiento futuro | 0/6 |
| Rendimiento pasado | 0/6 |
| Salud financiera | 5/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
LUNG Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Pulmonx Corporation
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$1.27 |
| Máximo en las últimas 52 semanas | US$3.88 |
| Mínimo de 52 semanas | US$1.13 |
| Beta | 0.31 |
| Cambio en 1 mes | -0.78% |
| Variación en 3 meses | -2.31% |
| Cambio de 1 año | -60.80% |
| Variación en 3 años | -89.91% |
| Variación en 5 años | -96.70% |
| Variación desde la OPV | -96.77% |
Noticias y actualizaciones recientes
Actualización de narrativa • Jul 09
LUNG: Index Reclassification And Improved Margins Will Support Future Upside
Analysts have adjusted their Pulmonx price target from $5.17 to $3.40, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for Pulmonx Pulmonx was dropped from several Russell growth oriented benchmarks, including the Russell 3000 Growth, Russell 2000 Growth, Russell 2500 Growth, Russell 3000E Growth, Russell Small Cap Comp Growth, Russell 2000 Dynamic Index, and Russell Small Cap Completeness Index.
Actualización de narrativa • Jun 25
LUNG: 2026 Revenue Reaffirmation Will Support Confidence In Earnings Turnaround
Analysts have maintained their $5.00 price target on Pulmonx, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that, taken together, support keeping fair value at $5.00. What’s in the News for Pulmonx Pulmonx reaffirmed earnings guidance for fiscal 2026, indicating revenue expectations remain unchanged.Actualización de narrativa • Jun 07
LUNG: Reset Expectations And 2026 Guidance Will Underpin Turnaround Confidence
Analysts have reset their price target on Pulmonx from about $13.26 to $5.00 as they now apply lower revenue growth assumptions, slightly tighter discounting, and a modestly reduced future P/E multiple in their models. What's in the News Pulmonx reaffirmed earnings guidance for fiscal 2026 and said it continues to expect full-year revenue in the range of $90 million to $92 million.Recent updates
Actualización de narrativa • Jul 09
LUNG: Index Reclassification And Improved Margins Will Support Future Upside
Analysts have adjusted their Pulmonx price target from $5.17 to $3.40, citing updated assumptions for discount rates, revenue growth, profit margins, and future P/E expectations. What’s in the News for Pulmonx Pulmonx was dropped from several Russell growth oriented benchmarks, including the Russell 3000 Growth, Russell 2000 Growth, Russell 2500 Growth, Russell 3000E Growth, Russell Small Cap Comp Growth, Russell 2000 Dynamic Index, and Russell Small Cap Completeness Index.Actualización de narrativa • Jun 25
LUNG: 2026 Revenue Reaffirmation Will Support Confidence In Earnings Turnaround
Analysts have maintained their $5.00 price target on Pulmonx, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E that, taken together, support keeping fair value at $5.00. What’s in the News for Pulmonx Pulmonx reaffirmed earnings guidance for fiscal 2026, indicating revenue expectations remain unchanged.Actualización de narrativa • Jun 07
LUNG: Reset Expectations And 2026 Guidance Will Underpin Turnaround Confidence
Analysts have reset their price target on Pulmonx from about $13.26 to $5.00 as they now apply lower revenue growth assumptions, slightly tighter discounting, and a modestly reduced future P/E multiple in their models. What's in the News Pulmonx reaffirmed earnings guidance for fiscal 2026 and said it continues to expect full-year revenue in the range of $90 million to $92 million.Actualización de narrativa • May 24
LUNG: Fundamentals Refocus And Internal Fixes Will Support Future Turnaround Confidence
Analysts recently cut their Pulmonx price target to $5 from $6, pointing to Q4 results that were largely in line with expectations while management works through internal issues and refocuses on the fundamentals that previously supported the business. Analyst Commentary Recent research points to a more measured, but still constructive, stance toward Pulmonx.Actualización de narrativa • May 02
LUNG: Execution Improvements And Fundamentals Focus Will Support Future Turnaround Confidence
Analysts have trimmed their price target on Pulmonx to $5 from $6, reflecting Q4 results that were largely in line and management's efforts to address internal issues while refocusing on the fundamentals that previously supported the business. Analyst Commentary Bullish analysts are emphasizing that the trimmed US$5 price target still reflects confidence that Pulmonx can execute on its plan to resolve internal issues and refocus on the fundamentals that previously supported the business.Actualización de narrativa • Apr 18
LUNG: Fundamental Reset And Cleaner Execution Will Support Future Upside
Analysts have trimmed their Pulmonx price target to $5 from $6, citing largely in line Q4 results, management's explanation of last year's internal issues, and the company's renewed focus on the fundamentals that supported its earlier success. Analyst Commentary Bullish Takeaways Bullish analysts view the reset to a US$5 price target as reflecting a more grounded expectation for execution, with Q4 results described as largely in line rather than a negative surprise.Actualización de narrativa • Apr 04
LUNG: Cleaner Execution And Fundamentals Refocus Will Support Future Upside
Analysts have trimmed their price target on Pulmonx to $5 from $6, pointing to Q4 results that were largely in line and to management's efforts to fix last year's internal issues while refocusing on the core fundamentals of the business. Analyst Commentary Bullish Takeaways Bullish analysts highlight that Q4 results being largely in line supports the current valuation reset, even with the lower US$5 price target.Actualización de narrativa • Mar 21
LUNG: Cleaner Execution And 2026 Revenue Guidance Will Support Future Upside
Analysts have trimmed their price target on Pulmonx to about $5.17 from $5.75, reflecting updated views on revenue growth, profit margin expectations, and the impact of recent operational issues highlighted in Q4 commentary. Analyst Commentary Recent research suggests that the lower price target reflects a reset of expectations around execution while still acknowledging the core business case.Actualización de narrativa • Mar 06
LUNG: Operational Reset And Fundamentals Focus Will Support Turnaround Confidence
Analysts have lowered their price target on Pulmonx by $1 to $5, citing Q4 results that were broadly in line with expectations, while management works through internal issues and refocuses on the fundamentals that previously supported the business. Analyst Commentary Recent research points to a more cautious, but still constructive, stance on Pulmonx.Actualización de narrativa • Feb 20
LUNG: Refined Risk And Margin Outlook Will Support Turnaround Confidence
Analysts have adjusted their Pulmonx price targets to reflect updated assumptions on discount rate, revenue growth, profit margin, and future P/E, keeping fair value around $13.49 while fine tuning the risk and earnings profile in their models. Valuation Changes Fair Value: Model fair value is unchanged at $13.49, indicating updated inputs did not shift the overall valuation level.Artículo de análisis • Feb 11
Pulmonx Corporation (NASDAQ:LUNG) Not Doing Enough For Some Investors As Its Shares Slump 29%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...Actualización de narrativa • Feb 06
LUNG: Firm Guidance And Margins Will Support Future Upside Potential
Analysts have kept their Pulmonx fair value estimate steady at US$5.75, with a slightly higher discount rate and P/E assumptions guiding the updated price target rationale. What's in the News Pulmonx issued new earnings guidance for full year 2025, setting an expected total revenue range of US$89 million to US$90 million.Actualización de narrativa • Jan 23
LUNG: Prior Leadership Return Will Drive Confidence In Turnaround Story
Narrative Update on Pulmonx Analysts have cut their price target on Pulmonx from $8 to $4, pointing to revised fair value assumptions and a lower future P/E multiple. At the same time, they highlight prior leadership returning and continued confidence in the Zephyr valves concept and the broader market opportunity.Artículo de análisis • Jan 10
Does Pulmonx (NASDAQ:LUNG) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Actualización de narrativa • Jan 08
LUNG: Returning Leadership And Clinical Traction Will Support Future Upside Potential
Analysts have trimmed their price target on Pulmonx to US$4.00 from US$8.00, citing a reassessment of valuation, the return of prior leadership, and ongoing confidence in the clinical proof of concept for Zephyr valves and the broader market opportunity. Analyst Commentary Recent research commentary focuses on how the lower price target, leadership changes, and clinical track record of Zephyr valves fit together for investors weighing risk and potential reward.Actualización de narrativa • Dec 24
LUNG: Returning Leadership Will Drive Confidence Amid Near-Term Execution Uncertainty
Analysts have reduced their price target on Pulmonx to approximately $4.00 from $8.00, citing near term uncertainty around leadership changes but continued confidence in the long term opportunity, supported by Zephyr valve clinical validation and the broader product pipeline. Analyst Commentary Bullish Takeaways Bullish analysts highlight that even after the reduced price target, the implied upside still represents roughly a potential doubling from recent after hours trading levels, which underscores a favorable risk reward profile.Actualización de narrativa • Dec 10
LUNG: Returning Leadership Will Drive Confidence And Unlock Significant Upside Ahead
Analysts have reduced their price target on Pulmonx to about $4 from roughly $8, citing a lower discount rate along with confidence in returning leadership, robust clinical validation of Zephyr valves, and a solid market and pipeline opportunity that they still see as supporting substantial upside from current levels. Analyst Commentary Bullish Takeaways Bullish analysts highlight that the lowered price target still implies meaningful upside from current trading levels, suggesting the market may be underestimating the company’s long term earnings potential.Artículo de análisis • Dec 05
Improved Revenues Required Before Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Jump Looks Justified
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has done very well over the last month, posting an excellent gain...Actualización de narrativa • Nov 26
LUNG: Returning Leadership Will Restore Confidence And Unlock Upside In Coming Year
Analysts have revised their price target for Pulmonx downward from $8 to $4 per share. They cite ongoing confidence in the company's clinical proof of concept and market opportunities, even in light of unexpected executive changes.Actualización de narrativa • Nov 12
LUNG: Leadership Transition Will Drive Renewed Execution Strength In The Coming Year
Analysts have revised Pulmonx’s price target downward from $8.00 to $4.00. They cite both leadership changes and ongoing belief in the company’s clinical achievements and long-term market potential as rationale for the adjustment.Actualización de narrativa • Oct 29
Leadership Return And Clinical Strength Will Drive Long-Term Market Opportunity
Analysts have lowered their price target for Pulmonx from $6.75 to $5.75, reflecting adjusted expectations on revenue growth and valuation. They remain optimistic, however, due to strong clinical evidence and a promising leadership transition.Artículo de análisis • Aug 28
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Jul 24
Pulmonx Corporation (NASDAQ:LUNG) Soars 47% But It's A Story Of Risk Vs Reward
Those holding Pulmonx Corporation ( NASDAQ:LUNG ) shares would be relieved that the share price has rebounded 47% in...Artículo de análisis • May 26
Pulmonx Corporation (NASDAQ:LUNG) Stock's 40% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Pulmonx Corporation ( NASDAQ:LUNG ) share price has dived 40% in the last...Artículo de análisis • Apr 11
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 29%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...
Nueva narrativa • Apr 01
LungTrax And Global Expansion Will Broaden Market Access
Expansion into new markets and innovative tools like LungTrax could grow patient volume, boosting revenue and operational efficiency.Artículo de análisis • Feb 21
Pulmonx Corporation (NASDAQ:LUNG) Just Reported Full-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Shareholders of Pulmonx Corporation ( NASDAQ:LUNG ) will be pleased this week, given that the stock price is up 19% to...Artículo de análisis • Feb 07
Many Still Looking Away From Pulmonx Corporation (NASDAQ:LUNG)
There wouldn't be many who think Pulmonx Corporation's ( NASDAQ:LUNG ) price-to-sales (or "P/S") ratio of 3.2x is worth...Artículo de análisis • Oct 22
Not Many Are Piling Into Pulmonx Corporation (NASDAQ:LUNG) Stock Yet As It Plummets 27%
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...Artículo de análisis • Oct 02
Is Pulmonx (NASDAQ:LUNG) Using Debt In A Risky Way?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Artículo de análisis • Aug 15
Pulmonx Corporation (NASDAQ:LUNG) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
Unfortunately for some shareholders, the Pulmonx Corporation ( NASDAQ:LUNG ) share price has dived 26% in the last...Seeking Alpha • Jul 21
Pulmonx: Low Bar For Q2 Earnings
Summary New CEO suggests status quo with respect to corporate strategy. Upcoming Q2 earnings have low expectations, which could provide a short-term positive catalyst. However, longer-term, the main issue with Pulmonx remains the mismatch between revenues and expenses. Read the full article on Seeking AlphaArtículo de análisis • Jun 07
Slammed 26% Pulmonx Corporation (NASDAQ:LUNG) Screens Well Here But There Might Be A Catch
The Pulmonx Corporation ( NASDAQ:LUNG ) share price has fared very poorly over the last month, falling by a substantial...Artículo de análisis • Apr 04
Pulmonx Corporation's (NASDAQ:LUNG) Share Price Matching Investor Opinion
You may think that with a price-to-sales (or "P/S") ratio of 4.5x Pulmonx Corporation ( NASDAQ:LUNG ) is a stock to...Rentabilidad de los accionistas
| LUNG | US Medical Equipment | Mercado US | |
|---|---|---|---|
| 7D | -14.2% | 1.7% | -0.7% |
| 1Y | -60.8% | -20.1% | 17.3% |
Rentabilidad vs. Industria: Los resultados de LUNG fueron inferiores a los de la industria US Medical Equipment, que obtuvo un rendimiento del -20.1% el año pasado.
Rentabilidad vs. Mercado: LUNG obtuvo unos resultados inferiores a los del mercado US, que fueron del 17.3% el año pasado.
Volatilidad de los precios
| LUNG volatility | |
|---|---|
| LUNG Average Weekly Movement | 10.6% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.2% |
Precio estable de las acciones: LUNG no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de LUNG (11%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1995 | 296 | Glen French | pulmonx.com |
Pulmonx Corporation, empresa de tecnología médica en fase comercial que ofrece un tratamiento mínimamente invasivo para pacientes con enfisema grave, una forma de enfermedad pulmonar obstructiva crónica. Ofrece la válvula endobronquial Zephyr; y el sistema de evaluación pulmonar Chartis, un catéter de balón y sistema de consola con sensores de flujo y presión que se utilizan para evaluar la presencia de ventilación colateral. La empresa también ofrece LungTraX Platform, un servicio de análisis cuantitativo de tomografía computarizada basado en la nube que proporciona a los médicos múltiples productos, como LungTraX Connect para mejorar la eficiencia de los exámenes; LungTraX Detect para permitir la identificación del paciente; y StratX Lung report que está diseñado para la solución que incluye información sobre la destrucción del enfisema, la integridad de las fisuras y el volumen lobar para ayudar a identificar los lóbulos objetivo para el tratamiento con las válvulas Zephyr.
Resumen de fundamentos de Pulmonx Corporation
| Estadísticas fundamentales de LUNG | |
|---|---|
| Capitalización bursátil | US$57.23m |
| Beneficios(TTM) | -US$53.21m |
| Ingresos (TTM) | US$88.55m |
0.6x
Ratio precio-ventas (PS)-1.0x
Ratio precio-beneficio (PE)¿Está LUNG sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de LUNG | |
|---|---|
| Ingresos | US$88.55m |
| Coste de los ingresos | US$21.70m |
| Beneficio bruto | US$66.84m |
| Otros gastos | US$120.05m |
| Beneficios | -US$53.21m |
Últimos beneficios comunicados
Mar 31, 2026
Próxima fecha de beneficios
Jul 29, 2026
| Beneficios por acción (BPA) | -1.26 |
| Margen bruto | 75.49% |
| Margen de beneficio neto | -60.09% |
| Ratio deuda/patrimonio | 81.5% |
¿Cómo se ha desempeñado LUNG a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/07/21 12:11 |
| Precio de las acciones al final del día | 2026/07/21 00:00 |
| Beneficios | 2026/03/31 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Pulmonx Corporation está cubierta por 11 analistas. 5 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Travis Steed | BofA Global Research |
| William Plovanic | Canaccord Genuity |
| John Young | Canaccord Genuity |